88 related articles for article (PubMed ID: 19438754)
21. A rare IgM multiple myeloma with aberrant PAX5 expression mimicking lymphoplasmacytic lymphoma.
Xu Z; Van Der Jagt R; Faught C; Beaulieu Bergeron M
Ann Hematol; 2014 Jul; 93(7):1251-2. PubMed ID: 24240978
[No Abstract] [Full Text] [Related]
22. The cellular architecture of multiple myeloma.
Vicente-Dueñas C; Romero-Camarero I; García-Criado FJ; Cobaleda C; Sánchez-García I
Cell Cycle; 2012 Oct; 11(20):3715-7. PubMed ID: 22983005
[No Abstract] [Full Text] [Related]
23. [Multiple myeloma -- diagnostics].
Schroers R; Zettl F; Jung W
Dtsch Med Wochenschr; 2005 Feb; 130(6):278-82; quiz 287-90. PubMed ID: 15692902
[No Abstract] [Full Text] [Related]
24. NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma.
Huang Z; Wu H; Chuai S; Xu F; Yan F; Englund N; Wang Z; Zhang H; Fang M; Wang Y; Gu J; Zhang M; Yang T; Zhao K; Yu Y; Dai J; Yi W; Zhou S; Li Q; Wu J; Liu J; Wu X; Chan H; Lu C; Atadja P; Li E; Wang Y; Hu M
Cancer Res; 2013 Oct; 73(20):6277-88. PubMed ID: 23980095
[TBL] [Abstract][Full Text] [Related]
25. Loss of p53 exacerbates multiple myeloma phenotype by facilitating the reprogramming of hematopoietic stem/progenitor cells to malignant plasma cells by MafB.
Vicente-Dueñas C; González-Herrero I; García Cenador MB; García Criado FJ; Sánchez-García I
Cell Cycle; 2012 Oct; 11(20):3896-900. PubMed ID: 22983007
[TBL] [Abstract][Full Text] [Related]
26. FOXP1 inhibits plasma cell differentiation.
Toellner KM
Blood; 2015 Oct; 126(18):2076-7. PubMed ID: 26516214
[No Abstract] [Full Text] [Related]
27. Regulation of cardiomyocyte proliferation by Foxp1.
Wang Y; Morrisey E
Cell Cycle; 2010 Nov; 9(21):4251-2. PubMed ID: 21051948
[No Abstract] [Full Text] [Related]
28. Unexpected steps in plasma-cell differentiation.
Klein U; Dalla-Favera R
Immunity; 2007 May; 26(5):543-4. PubMed ID: 17521580
[TBL] [Abstract][Full Text] [Related]
29. Pseudo-Gaucher cells in light chain plasma cell myeloma.
Kuwatsuka Y; Suzuki R; Ichihashi R; Kodera Y
Am J Hematol; 2006 Jun; 81(6):468-9. PubMed ID: 16680751
[No Abstract] [Full Text] [Related]
30. Characterization of Foxp2-expressing cells in the developing spinal cord.
Morikawa Y; Hisaoka T; Senba E
Neuroscience; 2009 Sep; 162(4):1150-62. PubMed ID: 19463901
[TBL] [Abstract][Full Text] [Related]
31. Alteration of enhancer of polycomb 1 at 10p11.2 is one of the genetic events leading to development of adult T-cell leukemia/lymphoma.
Nakahata S; Saito Y; Hamasaki M; Hidaka T; Arai Y; Taki T; Taniwaki M; Morishita K
Genes Chromosomes Cancer; 2009 Sep; 48(9):768-76. PubMed ID: 19484761
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of microRNA-29c is associated with renal failure in multiple myeloma.
Zhang S; Wu S; Qu X; Zhao M; Xu J; Jianyong L; Lijuan C
Leuk Lymphoma; 2014 Jan; 55(1):226-8. PubMed ID: 23656195
[No Abstract] [Full Text] [Related]
33. Foxp1 Is Required for Renal Intercalated Cell Differentiation and Acid-Base Regulation.
Wu ST; Feng Y; Song R; Qi Y; Li L; Lu D; Wang Y; Wu W; Morgan A; Wang X; Xia Y; Liu R; Alexander SI; Wong J; Zhang Y; Zheng X
J Am Soc Nephrol; 2024 May; 35(5):533-548. PubMed ID: 38332484
[TBL] [Abstract][Full Text] [Related]
34. [Clinical phenotype of a patient with FOXP1 deletion].
Blanco Sánchez T; Duat Rodríguez A; Cantarín Extremera V; Lapunzina P; Palomares Bralo M; Nevado Blanco J
An Pediatr (Barc); 2015 Apr; 82(4):280-1. PubMed ID: 25037997
[No Abstract] [Full Text] [Related]
35. FOXP2 as a molecular window into speech and language.
Fisher SE; Scharff C
Trends Genet; 2009 Apr; 25(4):166-77. PubMed ID: 19304338
[TBL] [Abstract][Full Text] [Related]
36. FOXD3 acts as a repressor of the mitochondrial S-adenosylmethionine carrier (SLC25A26) gene expression in cancer cells.
Cianciulli A; Menga A; Ferdinando P; Iacobazzi V
Biochimie; 2018 Nov; 154():25-34. PubMed ID: 30076902
[TBL] [Abstract][Full Text] [Related]
37. New technologies in the myeloma gene mine.
Van Ness B
Blood; 2002 Aug; 100(4):1109. PubMed ID: 12149181
[No Abstract] [Full Text] [Related]
38. Pseudohypopyon due to malignant infiltration of the anterior chamber in multiple myeloma.
Chan JH; Dua HS; Tranos PG; Jagger JD; Lim FL
Eye (Lond); 2005 Jan; 19(1):112-3. PubMed ID: 15105820
[No Abstract] [Full Text] [Related]
39. Characteristics, pathogenesis, and novel treatments for multiple myeloma.
San Miguel J
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S1-4. PubMed ID: 19791422
[TBL] [Abstract][Full Text] [Related]
40. Multiple myeloma with unusual inclusions.
Frotscher B; Salignac S; Lecompte T
Br J Haematol; 2009 Jan; 144(1):1. PubMed ID: 19006562
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
